Johnson & Johnson (JNJ)

2,530.00 +52.10 (+2.10%)
Closed MXN Disclaimer

Johnson & Johnson Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
152700
Equity Type
ORD
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Contact Information
Address
New Brunswick,08933 United States
Phone
732 524 0400
Fax
-
Top Executives
Name
Age
Since
Title
Joaquin Duato 60 2011 CEO & Chairman
Paula A. Johnson 63 2023 Independent Director
Mark B. McClellan 59 2013 Independent Director
Anne M. Mulcahy 71 2009 Lead Independent Director
Marillyn A. Hewson 69 2019 Independent Director
Jennifer A. Doudna 59 2018 Independent Director
Mary C. Beckerle 68 2015 Independent Director
Mark Alan Weinberger 61 2019 Independent Director
D. Scott Davis 71 2014 Independent Director
Darius E. Adamczyk 57 2022 Independent Director
Hubert Joly 64 2019 Independent Director
Nadja Y. West 62 2020 Independent Director
Paula A. Johnson 63 2023 Independent Director
Eugene A. Woods 59 2023 Independent Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.